Mme Docteur Amélie WETZMAN

Bibliographie

• Risk of cancer in patients with rheumatoid arthritis under tocilizumab: data from the French national registry REGATE

  2025

  ArticleJoint Bone Spine

• Risk of cancer after initiation of targeted therapies in patients with rheumatoid arthritis and a prior cancer: systematic review with meta‐analysis

  2021

  ArticleArthritis Care & Research = Arthritis Care and Research

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

• CABINET DU DR DAVID POUJOL

  17 AVENUE DE LA VOIE DOMITIENNE, 34500 Béziers

  Libéral
  © OpenStreetMap

  📷 Street View ↗🗺️ Maps ↗OSM ↗

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis

  Arthritis care & research · 2023

  📚 18 citations🎯 RCR 2.71Top 18% NIH🔓 Open Access

  Lire l'abstract Crossref ↓

  ObjectiveTo determine the risk of recurrent or new malignancy with exposure to targeted disease‐modifying antirheumatic drugs (DMARDs) in adults with rheumatoid arthritis (RA), axial spondyloarthritis (SpA), or psoriatic arthritis (PsA) and a history of cancer.MethodsWe performed a systematic search of the literature for articles published up to June 2019 that investigated adults with RA, axial SpA, or PsA who had a history of cancer and received biologic or targeted synthetic DMARDs (bDMARDs or tsDMARDs). We compared the risk of relapse or occurrence of new cancer between patients with and without bDMARDs. Rate ratios (RRs) with 95% confidence intervals (95% CIs) were estimated. The heterogeneity of the studies was evaluated by the Cochran Q test and the I2 statistic.ResultsWe included 24 observational studies of chronic inflammatory arthritis; of those, 12 were included in the meta‐analysis of RA patients receiving bDMARDs. As compared with RA patients with a history of cancer and not receiving bDMARDs, for those receiving any bDMARD, the overall RR for risk of neoplasia was 1.09 (95% CI 0.92–1.32; P = 0.31, I2 = 8%); with tumor necrosis factor inhibitors, it was 1.11 (95% CI 0.85–1.46; P = 0.45, I2 = 48%); and with rituximab, it was 0.79 (95% CI 0.41–1.53; P = 0.49, I2 = 0%). The RR for risk of recurrence for skin cancer was 1.32 (95% CI 1.02–1.72; P = 0.04, I2 = 0%) and for breast neoplasia 1.21 (95% CI 0.84–1.72; P = 0.31, I2 = 0%).ConclusionApart from skin cancers including melanoma, the risk of recurrent or new cancer is not increased with the initiation of bDMARDs for RA as compared with no bDMARDs.

• 2

  Risk of cancer in patients with rheumatoid arthritis under tocilizumab: Data from the French national registry REGATE

  Joint bone spine · 2025

  📚 1 citations

Publications scientifiques (2) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche